Orexin Receptor 2 Agonist Improves Sleepiness in Narcolepsy
For patients with narcolepsy type 1, TAK-994 improves measures of sleepiness and cataplexy over 8 weeks compared with placebo.
Source: neurologyadvisor.com
Page 5 - Wakefulness Test News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Wakefulness Test. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Wakefulness Test Today - Breaking & Trending Today
Trial Results Show Oral Orexin Receptor 2 -Selective Agonist Is Effective Over Placebo in Improving Wakefulness, Cataplexy in Patients With Narcolepsy Type 1
Despite the improvements in the patients' symptoms, minor adverse effects including urinary urgency and liver-related issues were reported.
Source: pharmacytimes.com
Orexin Receptor 2 Agonist Improves Sleepiness in Narcolepsy
Improvement seen in measures of sleepiness, cataplexy over eight weeks versus placebo, but drug was associated with hepatotoxic effects.
Source: empr.com
Narcolepsy Drug Candidate Promising But Raises Liver Concerns
In narcolepsy patients, TAK-994 showed significant improvements in wakefulness and reduced cataplexy rates but had hepatotoxic effects.
Source: sleepreviewmag.com
Narcolepsy Symptoms Normalize With Novel Agent
Neuropeptide drug stumbles on safety in phase II but stirs hope with 'truly remarkable effect'
Source: medpagetoday.com